<DOC>
	<DOC>NCT02761187</DOC>
	<brief_summary>The purpose of this study is to describe contemporary, real-world disease and participant presentation, therapies, and clinical outcomes in both participants with newly diagnosed and not yet relapsed [ND] multiple myeloma (MM), and participants with relapsed/refractory [R/R] MM.</brief_summary>
	<brief_title>An Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Participants</brief_title>
	<detailed_description>This is a non-interventional, observational. This study will look at contemporary, real-world presentation, therapies, and clinical outcomes in participants with MM. Participants will not be asked to change their routine clinical treatment. Participants will have to complete a patient self-reported outcomes (PROs) survey at home or during routine visits. The study will enroll approximately 5000 participants. Participants will be assigned to one of the following cohorts based upon the diagnosis of MM: - ND MM - R/R MM This multi-center trial will be conducted worldwide. The overall time to participate in this study is 5 years. Participants will be evaluated and followed-up for a period of at least 5 years, until death, or the end of the study, whichever comes first.</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms, Plasma Cell</mesh_term>
	<criteria>Is 18 years of age or older. Is newly diagnosed and not yet relapsed MM with documented month and year of diagnosis, criteria met for diagnosis, stage, and MMdirected treatment history, including duration, or Has relapsed/refractory MM with documented data in the medical record regarding diagnosis (month and year), prior exposure to classes of medications (example, proteosome inhibitors, immunomodulatory drugs), and number of previous lines of therapies. Is willing and able to sign informed consent to participate. Is willing and able to complete patient assessment questionnaires. Is reporting to a site in this study for a second opinion (consultation only) or participants whose frequency of consult and followup are not adequate for quarterly electronic case report form (eCRF) completion. Has participated in another study (observational or interventional) that prohibits participation in this study. Is unable or unwilling to complete health related quality of life (HRQoL) and Patient selfreported outcomes (PROs).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Drug Therapy</keyword>
</DOC>